STAT+: Pharmalittle: We’re reading about obesity pill trial results, cholesterol guidelines, and more
Why it matters: A 16% weight loss could reshape obesity treatment and curb related health crises.
- Structure Therapeutics unveiled a 44‑week trial where its daily pill achieved ~16% weight loss versus placebo
- Obesity patients could soon have a potent, prescription‑only tool alongside lifestyle changes
- Medical community sees the data as a potential bridge between modest diet‑based results and dramatic surgical outcomes
Structure Therapeutics reported that its once‑daily obesity pill shaved roughly 16% off participants’ body weight versus placebo after 44 weeks, a result that could mark a turning point in medical weight loss. The trial’s scale fuels optimism that drugs may finally keep pace with the escalating obesity epidemic.
